^
Association details:
| Biomarker: | MAP2K1 mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
Published date:
05/24/2021
Excerpt:
A standard 3 + 3 dose-escalation design was used. Binimetinib 30 mg BID (dose level 1 [DL1]) or 45 mg BID (dose level 2 [DL2]) was given with standard doses of carboplatin and pemetrexed using an intermittent dosing schedule....In an exploratory analysis, KRAS/NRAS-mutated patients had an ORR of 62.5% (ORR 37.5% by IR) vs. 25% in KRAS/NRAS wild-type patients.
Secondary therapy:
carboplatin + pemetrexed
DOI:
10.1016/j.lungcan.2021.05.021
Trial ID:
